The Urgent Need for Triple-Negative Breast Cancer Breakthroughs with Dr. Elisa Port

Triple negative breast cancer (TNBC) makes up about 15 percent of all the breast cancers diagnosed. And, better therapeutic strategies are urgently needed to treat this breast cancer subtype. BCRF Investigator, Dr. Elisa Port is working to combat drug resistance in TNBC by developing a drug for the protein PRKCQ—a promising therapeutic target that may make TNBC more responsive to chemotherapy.

Share | Download(Loading)

Episodes Date

Load more

Podbean App

Play this podcast on Podbean App